title: [New treatment protocols and follow-up in patients with exudative age-related macular degeneration].
abstract: Intravitreal ranibizumab (Lucentis®) injections are the treatment of choice in patients with exudative macular degeneration. In the last few years, several treatment and follow-up strategies have been evaluated with the aim of optimizing the safety and efficacy of this drug. In routine clinical practice, the Pro Re Nata (PRN) and treat-and-extend protocols or variants of the FUSION regimen have been used. PRN protocols are based on regular patient follow-up and on retreatment when there is evidence of reactivation of the lesion, basically determined by loss of visual acuity and persistent or recurrent macular fluid on optical coherence tomography. Treat-and-extend or FUSION protocols are based on early retreatment of the lesion before reactivation occurs with the aim of avoiding the irreversible visual loss that can occur in disease recurrences. There is no ideal treatment and follow-up protocol that could be used as an alternative to the monthly regimen and be applied and reproduced in all patients. Consequently, intravitreal ranibizumab therapy should be individualized in each patient.
authors: Servicio de Oftalmología, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, España; Sociedad Española de Retina y Vítreo (SERV). Electronic address: luisariasbarquet@gmail.com.
authors: L
authors: L
authors: Arias Barquet
authors: J
authors: J
authors: Monés
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D015415:Biomarkers; D002985:Clinical Protocols; D002986:Clinical Trials as Topic / Q000379:methods; D015331:Cohort Studies; D004334:Drug Administration Schedule; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000188:drug therapy*; D015337:Multicenter Studies as Topic / Q000379:methods; D057285:Precision Medicine; D000069579:Ranibizumab; D041623:Tomography, Optical Coherence; D057170:Translational Research, Biomedical; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; D000069579:Ranibizumab